1.
Collins R, Peto R, MacMahon S, et al. Blood pressure, stroke, and coronary heart disease. Part 2, Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet. 1990;335(8693):827–38. [PubMed: 1969567]
2.
Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360(9349):1903–13. [Erratum appears in Lancet 2003 Mar 22; 361(9362):1060] [PubMed: 12493255]
3.
Casas JP, Chua W, Loukogeorgakis S, et al. Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. Lancet. 2005;366(9502):2026–33. [PubMed: 16338452]
4.
Matchar DB, McCrory DC, Orlando LA, et al. Comparative Effectiveneness of Angiotensin-Converting Enzyme Inhibitors (ACEIs) and Angiotensin II Receptor Antagonists (ARBs) for Treating Essential Hypertension. Rockville, MD: Agency for Healthcare Research and Quality; Nov, 2007. [March 14, 2010]. Comparative Effectiveness Review No. 10. (Prepared by Duke Evidence-based Practice Center under Contract No. 290-02-0025.) Available at: http://www​.effectivehealthcare​.ahrq.gov/reports/final.cfm. [PubMed: 21348044]
5.
Matchar DB, McCrory DC, Orlando LA, et al. Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for treating essential hypertension. Ann Intern Med. 2008;148(1):16–29. [PubMed: 17984484]
6.
Sanders GD, Coeytaux R, Dolor RJ, et al. Angiotensin-Converting Enzyme Inhibitors (ACEIs), Angiotensin II Receptor Antagonists (ARBs), and Direct Renin Inhibitors for Treating Essential Hypertension: An Update. Rockville, MD: Agency for Healthcare Research and Quality; Jun, 2011. [August 8, 2011]. Comparative Effectiveness Review No. 34. (Prepared by the Duke Evidence-based Practice Center under Contract No. 290-02-0025.) AHRQ Publication No. 11-EHC063-EF. Available at: http://www​.effectivehealthcare​.ahrq.gov/reports/final.cfm. [PubMed: 21977520]
7.
Powers BJ, Coeytaux RR, Dolor RJ, et al. Updated report on comparative effectiveness of ACE inhibitors, ARBs, and direct renin inhibitors for patients with essential hypertension: much more data, little new information. J Gen Intern Med. 2011. Epub ahead of print, 6 December 2011. [PMC free article: PMC3358398] [PubMed: 22147122]
8.
Baker WL, Coleman CI, Kluger J, et al. Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors or angiotensin II-receptor blockers for ischemic heart disease. Ann Intern Med. 2009;151(12):861–71. [PubMed: 20008762]
9.
Robinson KA, Saldanha IJ, McKoy NA. Development of a framework to identify research gaps from systematic reviews. J Clin Epidemiol. 2011;64(12):1325–30. [PubMed: 21937195]
10.
Anonymous. DRAFT Methods Research on Future Research Needs Report. Rockville, MD: Agency for Healthcare Research and Quality; Sep, 2011. [February 3, 2012]. Framework for Considering Study Designs for Future Research Needs (FRN) Available at: http://www​.effectivehealthcare​.ahrq.gov/index​.cfm/search-for-guides-reviews-and-reports​/?pageaction=displayProduct&productID=774.
11.
Sanders GD, Powers B, Crowley M, et al. Future Research Needs for Angiotensin Converting Enzyme Inhibitors or Angiotensin II Receptor Blockers Added to Standard Medical Therapy for Treating Stable Ischemic Heart Disease. Rockville, MD: Agency for Healthcare Research and Quality; Nov, 2010. [January 19, 2012]. Future Research Needs Paper No. 8. (Prepared by Duke Evidence-based Practice Center under Contract No. 290-2007-10066-I.) AHRQ Publication No. 11-EHC006-EF. Available at: www​.effectivehealthcare​.ahrq.gov/reports/final.cfm. [PubMed: 21433330]
12.
Jong P, Demers C, McKelvie RS, et al. Angiotensin receptor blockers in heart failure: meta-analysis of randomized controlled trials. J Am Coll Cardiol. 2002;39(3):463–70. [PubMed: 11823085]
13.
Balamuthusamy S, Srinivasan L, Verma M, et al. Renin angiotensin system blockade and cardiovascular outcomes in patients with chronic kidney disease and proteinuria: a meta-analysis. Am Heart J. 2008;155(5):791–805. [PubMed: 18440325]
14.
Sipahi I, Debanne SM, Rowland DY, et al. Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials. Lancet Oncol. 2010;11(7):627–36. [PMC free article: PMC4070221] [PubMed: 20542468]